Clinical trials: Neuromyelitis Optica Spectrum Disorders
NMOSD, Neuromyelitis Optica Spectrum Disorders
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).
- Trial name
- ECU-NMO-304 (NCT06724809)
- Testing
- eculizumab
- Where
- 7 sites in China
- Volunteers
- 21 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica, Efgartigimod
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.
- Trial name
- NCT06118398
- Testing
- Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP
- Volunteers
- 24 people
- Sponsor
- Feng Jinzhou
Neuromyelitis Optica Spectrum Disease (NMOSD), Ripertamab
Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders
This clinical trial aims to evaluate the safety and efficacy of ripertamab in patients with neuromyelitis optica spectrum disorders (NMOSD). The key research objectives are as follows: 1.
- Trial name
- RIPERT-NMOSD (NCT07685678)
- Testing
- Ripertamab
- Volunteers
- 20 people
- Sponsor
- Zhongming Qiu
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
- Trial name
- NCT04201262
- Testing
- Ravulizumab
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 58 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
NMOSD
Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder
This study aims to evaluate the efficacy and safety of different monoclonal antibody in the acute phase of neuromyelitis optica spectrum disorder (MAAP-NMO).
- Trial name
- NCT07182409
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
NMO Spectrum Disorder
A Study of HBM9161 in NMOSD Patients
Primary Objectives:To investigate the safety and tolerability of HBM 9161 in patients with attack of NMOSD in China
- Trial name
- NCT04227470
- Testing
- HBM9161 Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
NMOSD
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain.
- Trial name
- BEST-NMOSD (NCT07010302)
- Testing
- Rituximab (R), Eculizumab (Soliris®), Ravulizumab
- Where
- 3 sites in United States, Germany
- Volunteers
- 540 people
- Sponsor
- Massachusetts General Hospital
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Maintenance Plasma Exchange for Neuromyelitis Optica
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4.
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
- Trial name
- MultiPLEX (NCT01500681)
- Testing
- Plasma exchange (PLEX)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Multiple Sclerosis, Neuromyelitis Optica
MS and NMOSD in African-Americans
This is a prospective study that aims to collect and review neuromyelitis optica spectrum disorder (NMOSD) data from African American patients with a known diagnosis of multiple sclerosis (MS).
- Trial name
- NCT04131673
- Where
- United States
- Sponsor
- Jagannadha R Avasarala
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- SAkuraSun (NCT05199688)
- Testing
- Satralizumab
- Where
- 14 sites in United States, Argentina and 7 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Neuromyelitis Optica Spectrum Disorder
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
The purpose of this proof of concept study is to assess the acceptability and safety of MR-C-014 in persons with Neuromyelitis optica spectrum disorder (NMOSD) who have a gait deficit.
- Trial name
- aNiMatO (NCT06374264)
- Testing
- MR-C-014
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedRhythms, Inc.
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- NCT06939166
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tianjin Huanhu Hospital
NMO Spectrum Disorder
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
The primary objective of this registry study is to evaluate the therapeutic efficacy and safety profiles of distinct monoclonal antibody-based therapies for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum…
- Trial name
- NCT06885957
- Testing
- Mab Therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
NMO Spectrum Disorder
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel.
- Trial name
- NCT05792462
- Testing
- Baricitinib
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica
Scrambler Trial for Pain in NMOSD
A novel technology called Scrambler Therapy is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of C fibers with the intent of re-organizing maladaptive signaling pathways.
- Trial name
- NCT03452176
- Testing
- Scrambler
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Neuromyelitis Optica
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
The purpose of this study is to determine the ability of STRATUS OCT and high resolution OCT to detect and to quantify the neural loss in multiple sclerosis and neuromyelitis optica and its subtypes.
- Trial name
- NCT01024985
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Demyelinating Diseases of the Central Nervous System (DDC)
Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)
Demyelinating Diseases of the Central Nervous System Registry for Patients with Traditional Chinese Medicine (DATE-TCM) is an observational study aiming to better define the multidimensional (epidemiologic, demographic and…
- Trial name
- NCT05415579
- Testing
- Traditional Chinese medicine (TCM)
- Volunteers
- 2,000 people
- Sponsor
- Dongzhimen Hospital, Beijing
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
This is an uncontrolled, prospective, observational cohort study to assess the function of meningeal lymphatic drainage and dynamics of immune cells in patients with relapsing multiple sclerosis (RMS) or Neuromyelitis optica…
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Demyelinating Diseases of the Central Nervous System
- Trial name
- OMNISCIENCE (NCT05414487)
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica, Restless Legs Syndrome
Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
Restless legs syndrome (RLS) is a neurological movement disorder characterized by uncomfortable and uncontrollable sensations, usually in the legs, that increase at rest, and an urge to move the legs or other affected…
- Trial name
- NCT05573711
- Testing
- assessments
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Dokuz Eylul University